ReviewDrugs1990
Isradipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cardiovascular disease.
Review in Drugs, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 93 citations in OpenAlex.
- Trial
- Influence of input rates on (+/-)-isradipine haemodynamics and concentration-effect relationship in healthy volunteers.European journal of clinical pharmacology · 1994Trial
- Dose titration study of isradipine in Chinese patients with mild to moderate essential hypertension.Cardiovascular drugs and therapy · 1993Trial
- Antihypertensive effect of once daily sustained release isradipine: a placebo controlled cross-over study.European journal of clinical pharmacology · 1993Trial
- Chronic neurotransmission increases the susceptibility of lateral-line hair cells to ototoxic insults.eLife · 2022Article
- Drug Repurposing in Parkinson's Disease.CNS drugs · 2018Review
- Neuromodulatory Inputs to Motoneurons Contribute to the Loss of Independent Joint Control in Chronic Moderate to Severe Hemiparetic Stroke.Frontiers in neurology · 2018Article
- Calcium and Parkinson's disease.Biochemical and biophysical research communications · 2017Review
- Differential CaMKII regulation by voltage-gated calcium channels in the striatum.Molecular and cellular neurosciences · 2015Article
- The ongoing pursuit of neuroprotective therapies in Parkinson disease.Nature reviews. Neurology · 2015Review
- Fabrication of isradipine nanosuspension by anti-solvent microprecipitation-high-pressure homogenization method for enhancing dissolution rate and oral bioavailability.Drug delivery and translational research · 2013Article
- Physiological phenotype and vulnerability in Parkinson's disease.Cold Spring Harbor perspectives in medicine · 2012Review
- The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease.Neuroscience · 2011Review
- The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.Neurobiology of disease · 2011Article
- The origins of oxidant stress in Parkinson's disease and therapeutic strategies.Antioxidants & redox signaling · 2011Review
- Calcium, cellular aging, and selective neuronal vulnerability in Parkinson's disease.Cell calcium · 2010Review
- Calcium homeostasis, selective vulnerability and Parkinson's disease.Trends in neurosciences · 2009Review
- A review of calcium channel antagonists in the treatment of pediatric hypertension.Paediatric drugs · 2006Review
- Clinical pharmacokinetics of vasodilators. Part I.Clinical pharmacokinetics · 1998Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Isradipine, a dihydropyridine derivative, inhibits the inward calcium flux through 'slow' channels of cardiac and vascular tissue, thereby eliciting potent coronary, cerebral and peripheral vasodilatation. In comparison with other calcium channel blockers the drug offers the advantages of minimal cardiodepressant activity, a selective action on the coronary and skeletal muscle vasculature, and a prolonged vasodilatory action. Clinical trials indicate that isradipine is an effective antihypertensive agent, suitable as monotherapy or in combination with beta-blockers, diuretics or ACE inhibitors, for long term treatment of mild to moderate hypertension. Preliminary findings suggest that the drug has a potential role in the treatment of chronic stable angina and, possibly, congestive heart failure. Adverse effects associated with the vasodilatory action of isradipine are generally mild, transient and well-tolerated, and are similar to those encountered with other calcium channel blockers. Thus, isradipine appears to offer a useful alternative to other dihydropyridine derivatives currently employed for the treatment of mild to moderate hypertension and, to a lesser extent, chronic stable angina. While its relative freedom from serious adverse effects may prove of value, its place in therapy vis-à-vis the established calcium channel blockers requires further clarification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.